Interestingly, Satoshi Endo and colleagues reported a higher NRF2 nuclear expression in cabazitaxel-resistant prostate cancer 22Rv1/Cab-R cells compared to the cabazitaxel sensitive 22Rv1 cells [146]. The gene discussed is NFE2L2; the disease is prostate cancer.